Relay Therapeutics, Inc. RLAY Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $10.68M+39.0% | $15.36M+53.5% | $8.36M-16.5% | $8.36M-76.3% | $7.68M-78.3% | ||
| $258.14M-16.9% | $261.38M-18.1% | $274.04M-16.6% | $282.4M-15.3% | $310.5M-5.8% | ||
| $49M-35.1% | $56.71M-26.0% | $61.4M-19.7% | $69.02M-8.2% | $75.53M+0.5% | ||
| $307.14M-18.0% | $318.09M-16.8% | $335.44M-13.9% | $351.42M-10.4% | $374.65M-5.8% | ||
| $307.14M-18.0% | $318.09M-16.8% | $335.44M-13.9% | $351.42M-10.4% | $374.65M-5.8% | ||
| -$296.46M+19.2% | -$302.74M+18.7% | -$327.09M+13.9% | -$343.06M+3.9% | -$366.97M-1.3% | ||
| -2,776.6%+2,002pp | -1,971.5%+1,751pp | -3,914.4%-120pp | -4,105.6%-3,092pp | -4,778.9%-3,754pp | ||
| $24.57M-26.9% | $27.04M-22.2% | $30.3M-12.1% | $32.17M-5.5% | $33.61M+1.7% | ||
| $23.75M-29.3% | $26.26M-24.5% | $29.49M-14.5% | $31.52M-7.5% | $33.59M+1.6% | ||
| -$272.71M+18.2% | -$276.48M+18.1% | -$297.59M+13.8% | -$311.55M+3.5% | -$333.39M-1.3% | ||
| -2,554.1%+1,787pp | -1,800.5%+1,574pp | -3,561.4%-112pp | -3,728.4%-2,812pp | -4,341.5%-3,410pp | ||
| -$1.56+29.1% | -$1.61+31.8% | -$1.72+34.1% | -$1.92+23.8% | -$2.20+16.7% | ||
| -$1.56+29.1% | -$1.61+31.8% | -$1.72+34.1% | -$1.92+23.8% | -$2.20+16.7% | ||
| 695.1M+18.8% | 684.5M+25.2% | 655.8M+24.6% | 623.6M+22.6% | 585.2M+17.7% | ||
| —— | —— | —— | —— | —— | ||
| -$272.18M+18.1% | -$274.76M+18.8% | -$299.61M+11.7% | -$310.37M+2.4% | -$332.19M-2.4% | ||
| $24.57M-26.9% | $27.04M-22.2% | $30.3M-12.1% | $32.17M-5.5% | $33.61M+1.7% | ||
| $523K-56.3% | $1.72M+317% | -$2.02M-134% | $1.18M-75.2% | $1.2M-74.2% | ||
| $523K-56.3% | $1.72M+317% | -$2.02M-134% | $1.18M-75.2% | $1.2M-74.2% | ||
| $23.75M-29.3% | $26.26M-24.5% | $29.49M-14.5% | $31.52M-7.5% | $33.59M+1.6% | ||
| $258.14M-16.9% | $261.38M-18.1% | $274.04M-16.6% | $282.4M-15.3% | $310.5M-5.8% | ||
| $10.68M+39.0% | $15.36M+53.5% | $8.36M-16.5% | $8.36M-76.3% | $7.68M-78.3% | ||
| 695.1M+18.8% | 684.5M+25.2% | 655.8M+24.6% | 623.6M+22.6% | 585.2M+17.7% | ||
| -$296.46M+19.2% | -$302.74M+18.7% | -$327.09M+13.9% | -$343.06M+3.9% | -$366.97M-1.3% | ||
| -$293.61M+18.8% | -$299.18M+18.5% | -$322.79M+13.7% | -$338.15M+3.8% | -$361.7M-1.4% | ||
| -$293.61M+18.8% | -$299.18M+18.5% | -$322.79M+13.7% | -$338.15M+3.8% | -$361.7M-1.4% | ||
| -2,749.9%+1,960pp | -1,948.3%+1,719pp | -3,863%-124pp | -4,046.8%-3,049pp | -4,710.2%-3,700pp | ||
| -$296.46M+19.2% | -$302.74M+18.7% | -$327.09M+13.9% | -$343.06M+3.9% | -$366.97M-1.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Relay Therapeutics, Inc.'s income statement data come from?
- Every line is extracted from Relay Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.